Category: Uncategorized

SBIR GRANTS have always been an important factor in financing many early stage biopharma companies. While increasingly competitive in recent years, this non-dilutive funding is often a green light to investors that the emerging company has competitive science and a drive to compete for future funding. http://lnkd.in/gE-zP6 View in LinkedIn

GREAT ADVICE EVERY ENTREPRENEUR MUST INTERNALIZE. These are the KEY questions to ask of a VC, period. You MUST get answers before you say yes to an investment. A wrong VC can wreck your company as quickly as no VC can. And remember, when you go for Series B, the VC investors you have selected will come under as much scrutiny as your company, and they can be a very fastidious bunch. http://lnkd.in/NfntTa View in LinkedIn

PUBLIC COMPANY PLEASE CEOs READ THIS! Capitalism at its worst is like fast food: bad for your company's health. That the culture of Wall Street breeds the short-term mentality of business CEOs focusing only on the next quarter results, is simply madness. Thank you, McKinsey, for generating contrarian data to suggest that this is, after all, just nonsense, and that building long-term value, an obviously sensible goal, does matter. Onwards and upwards! http://lnkd.in/D7tWnD View in LinkedIn

MENTORS COUNT for early stage entrepreneurs, and can really make the difference between success and failure, if you choose carefully. Also, with the odds stacked against you (the oft quoted stat that 90% of VC investments fail). if that happens, be prepared. If you have the temperament, get back on that horse and learn from your first mistakes. Write an analysis of what worked and what did not. Share that with a mentor and discuss. This B-School Class is live! http://lnkd.in/TrDFQv View in LinkedIn

OPEN INNOVATION CHALLENGE TO BIOPHARMACEUTICAL ENTREPRENEURS WORLDWIDE! Here is the KEY FACT: Only less than 2% of the potentially druggable sites on the human genome have been exploited. This is THE BOTTLENECK in unlocking the power of medicines to treat diseases. Can you devise a Paradigm Shift to be the next Disruptive Technology in pharmaceuticals? We need a new way of thinking. View in LinkedIn

BIG HEALTHCARE COMPANIES CONTINUED INTEREST IN EMERGING COMPANIES. Yes, empty pipelines and inefficient discovery programs make for this continuing trend and symbiotic relationship; and emerging companies need both the capital and the marketing muscle to continue to do what they do best: innovate cheaply. http://lnkd.in/qi6ZQb View in LinkedIn

THE POTENTIAL FOR NEW MEDICINES IS BARELY TOUCHED. The drugs on the worldwide market are inly some 1,500 discrete entities (not counting doses and formulations), and represent only a few hundred druggable targets, or less than 2% of the potential druggable targets in the human genome. This vast gap in potential is being closed at a snail's pace in terms of New Chemical Entities entering the market. Here is an opportunity for a PARADIGM SHIFT by some smart young entrepreneur. Unlock that potential and change the way we discover new treatments. View in LinkedIn

ARE INTERNATIONAL SALES IN YOUR STARTUP BIZ PLAN? You will need a strategic partnerships, as well illustrated in this article. I have sat through way too many presentations from startups who dream of foreign market shares based on the Mousetrap Model. The likelihood that you will have any ability to understand the market dynamics of a foreign culture is close to zero, let alone gain market share. If you must dream of this, please factor in a partner! http://lnkd.in/ZX4vBR View in LinkedIn

THINKING OF DOING AN MBA? See this great infographic. I get this question all the time and finally, I have a great resource to reference. Biz School will change the way you problem solve. It is valuable. Will that immediately translate into value? Unlikely. But it is a qualification that serves to boost your chances of a senior post when combined with valuable experience. http://lnkd.in/UaHHnV View in LinkedIn

SPANISH AND INDIAN INVESTORS JOIN FORCES. If you worry that the numbers are small, think again. Advinus (Tata) has already been leading the pack in putting risk capital to work to move up the food chain, Inveready has been an established Spanish investor for a long time. Tata bought UK LandRover motors and promises to do a better job. This current deal is a sign of things to come: a smaller world, greater alliances both of money and innovators. http://lnkd.in/DFXJZ8 View in LinkedIn